Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials

INTRODUCTION: Ipragliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM). The objective of this pooled analysis was to characterise the safety profile of ipragliflozin based on safety data from published randomised cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwagi, Atsunori, Shestakova, Marina V., Ito, Yuichiro, Noguchi, Masahiro, Wilpshaar, Wim, Yoshida, Satoshi, Wilding, John P. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848447/
https://www.ncbi.nlm.nih.gov/pubmed/31606880
http://dx.doi.org/10.1007/s13300-019-00699-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848447/
https://www.ncbi.nlm.nih.gov/pubmed/31606880
http://dx.doi.org/10.1007/s13300-019-00699-8

Ejemplares similares